Diligence memo · auto-generated · as of July 2, 2026
NeuroLambda Therapeutics, Inc.
NeuroLambda Therapeutics, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
NeuroLambda Therapeutics, Inc. operates in Pharma, based in Cambridge.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
NeuroLambda Therapeutics, Inc. has raised $3.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.0M on 2024-06-21.
Most recent recorded round closed around 2024-06-21.
Valuation (modeled)modeled
Provath models NeuroLambda Therapeutics, Inc. at approximately $14M (range $2.3M–$39M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.07× the median modeled value of Seed Pharma companies in 2022–2024 (18 peers) — value vs value, same stage and era. Within the normal band (107% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.0 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 49% of Pharma peers (310 compared).
Modeled value ranks above 40% of those peers.
Closest niche peers: Seal Rock Therapeutics, Inc., Diligent Pharma, Inc., A28 Therapeutics, Inc., Centaurus Therapeutics, Inc., Pathfinder Oncology, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.